Qingsheng Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qingsheng Yu has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Hui Peng
Department of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine
15 shared publicationsLong Huang
The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China
9 shared publicationsQi Zhang
Department of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine Hefei 230031, Anhui, P. R. China
9 shared publicationsYi Shen
Department of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine
9 shared publicationsZiyi Li
Department of General Surgery, Institute of Chinese Medicine Surgery
9 shared publicationsFuhai Zhou
6 shared publications
Latest Publications
- 16 October 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 236
Danshen Injection for 5-Fluorouracil-Resistant Gastric Cancer: Mitochondrial Apoptosis and Enhanced Drug Activity
Gastric cancer ranks among the leading causes of cancer-related death worldwide, and the progressive emergence of 5-fluorouracil (5-FU) resistance represents a critical barrier to the efficacy of conventional chemotherapy, particularly 5-FU-based regimens. Danshen injection (DI), a clinically approved intravenous preparation derived from Salvia miltiorrhiza, has demonstrated preliminary antineoplastic activity; however, the mechanistic basis underlying its reversal of 5-FU resistance in gastric cancer has not been systematically defined. This study aimed to evaluate the antitumor efficacy of DI and its potential for enhanced combined activity with 5-FU in human gastric cancer cell lines (SGC7901 and BGC823), their 5-FU-resistant variants, and a xenograft mouse model. DI significantly induced apoptosis in both parental and drug-resistant cell lines, while CCK-8 assays confirmed markedly elevated IC50 values in resistant variants, validating the chemoresistant phenotype. The combination of DI and 5-FU produced enhanced antitumor effects superior to either agent alone, as demonstrated by increased apoptotic rates, upregulated expression of cleaved PARP and cleaved caspase-3, impaired mitochondrial membrane potential by JC-10 assay, and reduced colony formation. Mechanistically, DI promoted cytochrome c translocation from mitochondria to the cytoplasm, and elevated cleaved caspase-9 levels, effects that were further amplified upon co-treatment with 5-FU. Consistent antitumor activity was validated in vivo, with the combination regimen demonstrating superior tumor suppression compared with monotherapy. Collectively, these findings demonstrate that DI exerts meaningful antitumor activity and produces a greater combined effect with 5-FU in 5-FU-resistant gastric cancer. This study provides a preclinical rationale for incorporating DI into chemotherapy-based strategies for the management of 5-FU-resistant gastric cancer.
- 16 October 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 236
Danshen Injection for 5-Fluorouracil-Resistant Gastric Cancer: Mitochondrial Apoptosis and Enhanced Drug Activity
Gastric cancer ranks among the leading causes of cancer-related death worldwide, and the progressive emergence of 5-fluorouracil (5-FU) resistance represents a critical barrier to the efficacy of conventional chemotherapy, particularly 5-FU-based regimens. Danshen injection (DI), a clinically approved intravenous preparation derived from Salvia miltiorrhiza, has demonstrated preliminary antineoplastic activity; however, the mechanistic basis underlying its reversal of 5-FU resistance in gastric cancer has not been systematically defined. This study aimed to evaluate the antitumor efficacy of DI and its potential for enhanced combined activity with 5-FU in human gastric cancer cell lines (SGC7901 and BGC823), their 5-FU-resistant variants, and a xenograft mouse model. DI significantly induced apoptosis in both parental and drug-resistant cell lines, while CCK-8 assays confirmed markedly elevated IC50 values in resistant variants, validating the chemoresistant phenotype. The combination of DI and 5-FU produced enhanced antitumor effects superior to either agent alone, as demonstrated by increased apoptotic rates, upregulated expression of cleaved PARP and cleaved caspase-3, impaired mitochondrial membrane potential by JC-10 assay, and reduced colony formation. Mechanistically, DI promoted cytochrome c translocation from mitochondria to the cytoplasm, and elevated cleaved caspase-9 levels, effects that were further amplified upon co-treatment with 5-FU. Consistent antitumor activity was validated in vivo, with the combination regimen demonstrating superior tumor suppression compared with monotherapy. Collectively, these findings demonstrate that DI exerts meaningful antitumor activity and produces a greater combined effect with 5-FU in 5-FU-resistant gastric cancer. This study provides a preclinical rationale for incorporating DI into chemotherapy-based strategies for the management of 5-FU-resistant gastric cancer.
- Open Access
Dietary Polyphenols as Adjunctive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Dietary polyphenols have been studied as adjunctive therapies for inflammatory bowel disease (IBD), but trials vary in formulation, clinical setting, and outcome definitions. We evaluated efficacy and safety separately for ulcerative colitis (UC) and Crohn’s disease (CD). Methods: We searched MEDLINE/PubMed, China National Knowledge Infrastructure (CNKI), Wanfang, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov through 20 August 2026. Risk of bias was assessed using Cochrane Risk of Bias 2 (RoB 2). Meta-analyses used MDs, SMDs, or ORs with 95% CIs. Quantitative synthesis was undertaken when studies were sufficiently comparable in clinical setting, outcome definition, and data structure; otherwise, results were summarized using study-level estimates. The protocol was registered with PROSPERO (CRD420261451126). Results: Twenty-one reports representing 19 randomized trials and 1048 participants were included. In conventional UC, polyphenols were associated with lower SCCAI scores (MD −1.32, 95% CI −1.81 to −0.83; I2 = 0%), whereas CRP/hs-CRP did not show a clear pooled effect (SMD 0.29, 95% CI −0.32 to 0.90; I2 = 83.7%). IBDQ-9 improved (MD 5.57, 95% CI 2.88 to 8.26). Clinical response favored supplementation (OR 4.90, 95% CI 3.04 to 7.89), as did induction of clinical remission (OR 5.98, 95% CI 3.08 to 11.59; I2 = 22.6%). Supplementation also favored endoscopic remission (OR 10.81, 95% CI 1.67 to 69.93; I2 = 69.4%), but the estimate was imprecise and sensitive to study-level risk of bias. In CD, the two randomized trials were not pooled due to targeting different clinical settings. Safety reporting was heterogeneous and sparse, with no consistent pattern of increased harm across trials. Conclusions: Curcumin has the most extensive adjunctive evidence base in UC but effect estimates for several outcomes were imprecise or sensitive to study design. Evidence in CD is still lacking.
Open AccessDietary Polyphenols as Adjunctive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Dietary polyphenols have been studied as adjunctive therapies for inflammatory bowel disease (IBD), but trials vary in formulation, clinical setting, and outcome definitions. We evaluated efficacy and safety separately for ulcerative colitis (UC) and Crohn’s disease (CD). Methods: We searched MEDLINE/PubMed, China National Knowledge Infrastructure (CNKI), Wanfang, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov through 20 August 2026. Risk of bias was assessed using Cochrane Risk of Bias 2 (RoB 2). Meta-analyses used MDs, SMDs, or ORs with 95% CIs. Quantitative synthesis was undertaken when studies were sufficiently comparable in clinical setting, outcome definition, and data structure; otherwise, results were summarized using study-level estimates. The protocol was registered with PROSPERO (CRD420261451126). Results: Twenty-one reports representing 19 randomized trials and 1048 participants were included. In conventional UC, polyphenols were associated with lower SCCAI scores (MD −1.32, 95% CI −1.81 to −0.83; I2 = 0%), whereas CRP/hs-CRP did not show a clear pooled effect (SMD 0.29, 95% CI −0.32 to 0.90; I2 = 83.7%). IBDQ-9 improved (MD 5.57, 95% CI 2.88 to 8.26). Clinical response favored supplementation (OR 4.90, 95% CI 3.04 to 7.89), as did induction of clinical remission (OR 5.98, 95% CI 3.08 to 11.59; I2 = 22.6%). Supplementation also favored endoscopic remission (OR 10.81, 95% CI 1.67 to 69.93; I2 = 69.4%), but the estimate was imprecise and sensitive to study-level risk of bias. In CD, the two randomized trials were not pooled due to targeting different clinical settings. Safety reporting was heterogeneous and sparse, with no consistent pattern of increased harm across trials. Conclusions: Curcumin has the most extensive adjunctive evidence base in UC but effect estimates for several outcomes were imprecise or sensitive to study design. Evidence in CD is still lacking.
- Open Access
- 16 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1787786
High-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects
Adoptive T cell therapy (ACT) is a potent strategy in cancer immunotherapy, but its clinical efficacy is often limited by primary resistance. To overcome this challenge, high-throughput screening technologies have emerged as essential tools for optimizing ACT. By enabling the identification of biologically significant targets and substances from vast libraries, these technologies have accelerated the development of advanced ACT strategies. This review delves into the latest advancements in high-throughput screening, highlighting its applications in genetic screening of T cells and tumor cells, as well as non-genetic screening for small molecules and targeted delivery systems. These insights provide valuable guidance for future research and clinical applications of ACT.
- 16 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1787786
Open AccessHigh-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects
Adoptive T cell therapy (ACT) is a potent strategy in cancer immunotherapy, but its clinical efficacy is often limited by primary resistance. To overcome this challenge, high-throughput screening technologies have emerged as essential tools for optimizing ACT. By enabling the identification of biologically significant targets and substances from vast libraries, these technologies have accelerated the development of advanced ACT strategies. This review delves into the latest advancements in high-throughput screening, highlighting its applications in genetic screening of T cells and tumor cells, as well as non-genetic screening for small molecules and targeted delivery systems. These insights provide valuable guidance for future research and clinical applications of ACT.
- 9 April 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 366, 121671
Qi-Huang decoction ameliorates renal injury in candidaemia via Dectin-1/NF-κB/IκBζ signaling pathway regulated by miR-32-5p
- 9 April 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 366, 121671
Qi-Huang decoction ameliorates renal injury in candidaemia via Dectin-1/NF-κB/IκBζ signaling pathway regulated by miR-32-5p
- Open Access
- 2 April 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Development and validation of an interpretable machine learning model for predicting portal vein system thrombosis following splenectomy in Wilson’s disease
Post-splenectomy portal vein system thrombosis (PVST) is a serious complication that adversely affects patient prognosis. The aim of this study was to develop and validate a machine learning-based model for early risk prediction of PVST after splenectomy. A total of 594 patients who underwent splenectomy were included in this study. The data were randomly divided into a training set (n = 417) and a validation set (n = 177) in a 7:3 ratio. Clinical characteristics associated with PVST risk were screened using LASSO regression and univariate analysis. Seven machine learning algorithms were applied for model training, and the models’ performance on the validation set was evaluated using the area under the curve (AUC), sensitivity, specificity, and F1 score. SHAP interpretability analyses and web-based deployment were used to derive clinical insights. In the training set, the key variables identified included splenomegaly grade, splenic thickness, portal vein flow velocity (PVV), portal vein diameter (PVD), portal vein flow (PVF), splenic vein diameter (SVD), postoperative platelet count (POD PLT), and postoperative D-dimer level (POD D-dimer). The XGBoost model outperformed the logistic regression (LR) and random forest (RF) models, achieving an AUC of 0.971 (95% CI: 0.950–0.987), accuracy of 92.8%, sensitivity of 91.2%, and specificity of 94.6%. In the validation set, the XGBoost model exhibited stable performance, with an AUC of 0.970, accuracy of 91.5%, precision of 89.9%, sensitivity of 88.6%, and specificity of 93.5%. the SHapley Additive exPlanations (SHAP) summary analysis indicated that PVV, PVF, and POD D-dimer were the top three predictors of PVST risk (SHAP Value = 0.076, 0.074 and 0.064). SHAP dependency plots and force plots provided explanations of the model’s predictions at the feature and individual levels, respectively. The XGBoost model demonstrated excellent discrimination and calibration for predicting PVST risk after splenectomy. It can serve as an early warning tool to identify high-risk patients, enabling timely interventions and improved clinical outcomes.
- 2 April 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Open AccessDevelopment and validation of an interpretable machine learning model for predicting portal vein system thrombosis following splenectomy in Wilson’s disease
Post-splenectomy portal vein system thrombosis (PVST) is a serious complication that adversely affects patient prognosis. The aim of this study was to develop and validate a machine learning-based model for early risk prediction of PVST after splenectomy. A total of 594 patients who underwent splenectomy were included in this study. The data were randomly divided into a training set (n = 417) and a validation set (n = 177) in a 7:3 ratio. Clinical characteristics associated with PVST risk were screened using LASSO regression and univariate analysis. Seven machine learning algorithms were applied for model training, and the models’ performance on the validation set was evaluated using the area under the curve (AUC), sensitivity, specificity, and F1 score. SHAP interpretability analyses and web-based deployment were used to derive clinical insights. In the training set, the key variables identified included splenomegaly grade, splenic thickness, portal vein flow velocity (PVV), portal vein diameter (PVD), portal vein flow (PVF), splenic vein diameter (SVD), postoperative platelet count (POD PLT), and postoperative D-dimer level (POD D-dimer). The XGBoost model outperformed the logistic regression (LR) and random forest (RF) models, achieving an AUC of 0.971 (95% CI: 0.950–0.987), accuracy of 92.8%, sensitivity of 91.2%, and specificity of 94.6%. In the validation set, the XGBoost model exhibited stable performance, with an AUC of 0.970, accuracy of 91.5%, precision of 89.9%, sensitivity of 88.6%, and specificity of 93.5%. the SHapley Additive exPlanations (SHAP) summary analysis indicated that PVV, PVF, and POD D-dimer were the top three predictors of PVST risk (SHAP Value = 0.076, 0.074 and 0.064). SHAP dependency plots and force plots provided explanations of the model’s predictions at the feature and individual levels, respectively. The XGBoost model demonstrated excellent discrimination and calibration for predicting PVST risk after splenectomy. It can serve as an early warning tool to identify high-risk patients, enabling timely interventions and improved clinical outcomes.
- Open Access
- 8 December 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Clinical application of a self- dislodging biliary stent for one-stage suturing following choledochotomy
Background Choledochal exploration remains a reliable and effective therapeutic strategy for the management of choledocholithiasis. Nevertheless, the optimal approach to bile duct closure following exploration—specifically the choice between T-tube drainage and primary suture closure—remains controversial, with no clear consensus established in current surgical practice. Objective This study aims to evaluate the safety and efficacy of self-detachable biliary stents in achieving primary closure following choledochotomy.Secondary research objective: Potential complications associated with the innovative surgical approach of using a self-dislodging biliary stent. Methods From January 2021 to May 2023, a total of 112 patients diagnosed with choledocholithiasis were enrolled in this study. Among them, 60 patients were assigned to the TTD group, in which laparoscopic choledochotomy with T-tube drainage was performed, while 52 patients were included in the PDC group, receiving primary duct closure combined with placement of a self-detachable biliary stent. Postoperative outcomes were compared between the two groups, including operative time, time to first defecation, length of hospital stay, perioperative changes in hematological and liver function parameters, as well as the incidence of complications such as intra-abdominal hemorrhage, bile leakage, electrolyte disturbances, and wound infection. Results There were no significant differences between the two groups with respect to operative time and intraoperative blood loss (P > 0.05). However, the time to first defecation and length of hospital stay were significantly shorter in the PDC group compared with the TTD group (P < 0.05). Postoperative WBC, TB, DB, and ALB levels did not differ significantly between the two groups (P > 0.05), whereas postoperative ALT, AST, and TBA levels were significantly different (P < 0.05). In addition, the overall incidence of postoperative complications was significantly lower in the PDC group than in the TTD group (P < 0.05). Conclusion Laparoscopic choledochal exploration followed by primary closure with a self-detachable biliary stent appears to be a safe, effective, and economically favorable strategy for the management of choledocholithiasis. This technique has the potential to serve as an alternative to conventional T-tube drainage, offering comparable safety while reducing postoperative complications and healthcare costs.
- 8 December 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Open AccessClinical application of a self- dislodging biliary stent for one-stage suturing following choledochotomy
Background Choledochal exploration remains a reliable and effective therapeutic strategy for the management of choledocholithiasis. Nevertheless, the optimal approach to bile duct closure following exploration—specifically the choice between T-tube drainage and primary suture closure—remains controversial, with no clear consensus established in current surgical practice. Objective This study aims to evaluate the safety and efficacy of self-detachable biliary stents in achieving primary closure following choledochotomy.Secondary research objective: Potential complications associated with the innovative surgical approach of using a self-dislodging biliary stent. Methods From January 2021 to May 2023, a total of 112 patients diagnosed with choledocholithiasis were enrolled in this study. Among them, 60 patients were assigned to the TTD group, in which laparoscopic choledochotomy with T-tube drainage was performed, while 52 patients were included in the PDC group, receiving primary duct closure combined with placement of a self-detachable biliary stent. Postoperative outcomes were compared between the two groups, including operative time, time to first defecation, length of hospital stay, perioperative changes in hematological and liver function parameters, as well as the incidence of complications such as intra-abdominal hemorrhage, bile leakage, electrolyte disturbances, and wound infection. Results There were no significant differences between the two groups with respect to operative time and intraoperative blood loss (P > 0.05). However, the time to first defecation and length of hospital stay were significantly shorter in the PDC group compared with the TTD group (P < 0.05). Postoperative WBC, TB, DB, and ALB levels did not differ significantly between the two groups (P > 0.05), whereas postoperative ALT, AST, and TBA levels were significantly different (P < 0.05). In addition, the overall incidence of postoperative complications was significantly lower in the PDC group than in the TTD group (P < 0.05). Conclusion Laparoscopic choledochal exploration followed by primary closure with a self-detachable biliary stent appears to be a safe, effective, and economically favorable strategy for the management of choledocholithiasis. This technique has the potential to serve as an alternative to conventional T-tube drainage, offering comparable safety while reducing postoperative complications and healthcare costs.
- Open Access
- 25 November 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1)
Risk factors and prediction model development for pancreatic fistula following splenectomy in Wilson’s disease patients with portal hypertension
Objective: Postoperative pancreatic fistula (POPF) following splenectomy in patients with Wilson’s disease (WD) complicated by portal hypertension adversely affects prognosis. Therefore, developing and validating an individualized nomogram to predict POPF risk is crucial. Methods: This retrospective study included 519 patients with WD-associated splenomegaly and hypersplenism who underwent splenectomy between January 2016 and June 2025. Patients were divided by center into a training cohort ( n = 411) and a validation cohort ( n = 108). Least absolute shrinkage and selection operator (LASSO) regression was used to select candidate variables, which were then incorporated into multivariable logistic regression to construct a predictive model and develop a nomogram. Shapley additive explanations (SHAP) were applied to interpret the selected variables. Restricted cubic spline (RCS) curves were used for threshold analysis of continuous variables. Model discrimination was evaluated using the area under the receiver operating characteristic curve (AUC). Calibration was assessed with calibration curves and the Hosmer-Lemeshow (HL) test, while clinical net benefit was determined via decision curve analysis (DCA). Predictive performance was compared with preoperative composite indices, including C-reactive protein to albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). Results: The overall incidence of POPF was 18.3% (95/519). LASSO regression identified seven variables: operation time, history of abdominal surgery, type of splenic hilum division, body mass index (BMI), splenomegaly grade, main pancreatic duct (MPD) diameter, and Clavien-Dindo classification (CDC) complications. Multivariable analysis revealed operation time (OR = 1.039), history of abdominal surgery (OR = 2.223), BMI (OR = 1.078), grade III splenomegaly (OR = 2.521), and CDC complications (OR = 1.726) as risk factors; type II splenic hilum division (OR = 0.494) and MPD diameter > 3 mm (OR = 0.509) as protective factors (all P < 0.05). SHAP interpretation indicated that operation time (+ 0.075) and history of abdominal surgery (+ 0.059) were the primary contributors to POPF prediction. RCS analysis highlighted BMI exceeding 24 kg/m² and operation time exceeding 200 min as key thresholds for increased POPF risk. The nomogram demonstrated AUC values of 0.761 (95% CI: 0.697–0.825) in the training cohort and 0.814 (95% CI: 0.702–0.927) in the validation cohort. The HL test yielded P = 0.615 and P = 0.410, respectively, indicating good calibration. DCA showed high net benefit in the training cohort at threshold probabilities of approximately 12%-91% and in the validation cohort at 15%-98%. Compared with CAR, NLR, and PLR, the nomogram exhibited superior AUC (0.761 vs. 0.621, 0.662, 0.633; DeLong test, all P < 0.05). Conclusion: The nomogram, constructed from a multivariable model, effectively discriminates and calibrates POPF risk following splenectomy in patients with WD, offering potential clinical utility. Particular attention should be paid to history of abdominal surgery and operation time, with preoperative individualized interventions tailored accordingly.
- 25 November 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1)
Open AccessRisk factors and prediction model development for pancreatic fistula following splenectomy in Wilson’s disease patients with portal hypertension
Objective: Postoperative pancreatic fistula (POPF) following splenectomy in patients with Wilson’s disease (WD) complicated by portal hypertension adversely affects prognosis. Therefore, developing and validating an individualized nomogram to predict POPF risk is crucial. Methods: This retrospective study included 519 patients with WD-associated splenomegaly and hypersplenism who underwent splenectomy between January 2016 and June 2025. Patients were divided by center into a training cohort ( n = 411) and a validation cohort ( n = 108). Least absolute shrinkage and selection operator (LASSO) regression was used to select candidate variables, which were then incorporated into multivariable logistic regression to construct a predictive model and develop a nomogram. Shapley additive explanations (SHAP) were applied to interpret the selected variables. Restricted cubic spline (RCS) curves were used for threshold analysis of continuous variables. Model discrimination was evaluated using the area under the receiver operating characteristic curve (AUC). Calibration was assessed with calibration curves and the Hosmer-Lemeshow (HL) test, while clinical net benefit was determined via decision curve analysis (DCA). Predictive performance was compared with preoperative composite indices, including C-reactive protein to albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). Results: The overall incidence of POPF was 18.3% (95/519). LASSO regression identified seven variables: operation time, history of abdominal surgery, type of splenic hilum division, body mass index (BMI), splenomegaly grade, main pancreatic duct (MPD) diameter, and Clavien-Dindo classification (CDC) complications. Multivariable analysis revealed operation time (OR = 1.039), history of abdominal surgery (OR = 2.223), BMI (OR = 1.078), grade III splenomegaly (OR = 2.521), and CDC complications (OR = 1.726) as risk factors; type II splenic hilum division (OR = 0.494) and MPD diameter > 3 mm (OR = 0.509) as protective factors (all P < 0.05). SHAP interpretation indicated that operation time (+ 0.075) and history of abdominal surgery (+ 0.059) were the primary contributors to POPF prediction. RCS analysis highlighted BMI exceeding 24 kg/m² and operation time exceeding 200 min as key thresholds for increased POPF risk. The nomogram demonstrated AUC values of 0.761 (95% CI: 0.697–0.825) in the training cohort and 0.814 (95% CI: 0.702–0.927) in the validation cohort. The HL test yielded P = 0.615 and P = 0.410, respectively, indicating good calibration. DCA showed high net benefit in the training cohort at threshold probabilities of approximately 12%-91% and in the validation cohort at 15%-98%. Compared with CAR, NLR, and PLR, the nomogram exhibited superior AUC (0.761 vs. 0.621, 0.662, 0.633; DeLong test, all P < 0.05). Conclusion: The nomogram, constructed from a multivariable model, effectively discriminates and calibrates POPF risk following splenectomy in patients with WD, offering potential clinical utility. Particular attention should be paid to history of abdominal surgery and operation time, with preoperative individualized interventions tailored accordingly.
- Open Access
- 16 October 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e76003
Prognostic Value of the Charlson Comorbidity Index for Mortality and Machine Learning–Based Prediction in Critically Ill Patients with Paralytic Ileus: Retrospective Cohort Study
Background: The burden of paralytic ileus (PI) in the intensive care unit remains high, and the Charlson Comorbidity Index (CCI) is strongly associated with the prognosis of several acute and chronic diseases. However, evidence specifically evaluating the prognostic value of CCI in intensive care unit patients with PI remains limited. Objective: This study aimed to investigate the association between CCI and clinical prognosis in critically ill patients with PI. Methods: In this study, data were extracted from the Medical Information Mart for Intensive Care IV (version 2.2), a large, publicly available critical care database, and used to determine the optimal cut-off value of CCI for predicting mortality in patients with PI using the receiver operating characteristic curves, and the association between CCI and mortality was evaluated using Cox regression and restricted cubic spline analysis. A machine learning (ML) prediction model was then constructed to predict hospital mortality by combining CCI and other clinical characteristics. Results: The study included 863 patients with PI (age: median 65.4, IQR 54.6‐75.5 y; male: 575/863, 66.6%). The receiver operating characteristic curve identified an optimal cut-off value of 4.5 for CCI. The multivariate Cox regression analysis showed that compared to the lowest CCI quartile, patients with elevated CCI levels were more likely to have elevated hospital (Q4: hazard ratio [HR] 2.447, 95% CI 1.210‐4.951), 28-day (Q4: HR 3.891, 95% CI 1.956‐7.740), and 90-day (Q4: HR 3.994, 95% CI 2.224‐7.173) all-cause mortality were significantly associated with elevated CCI levels; however, the association with ICU mortality (Q4: HR 1.892, 95% CI 0.653‐5.480) was weak. Among the 11 ML models, the light gradient boosting machine model performed best, with internal validation results showing an area under the curve of 0.811, a geometric mean of 0.670, and an F 1 -score of 0.895. Conclusions: The CCI is an important predictor of hospital, 28-day, and 90-day all-cause mortality in critically ill patients with PI, and the optimal threshold is 4.5. ML models, including the CCI, show high accuracy in predicting hospital mortality, and the CCI occupies an important position in the model. This suggests that the CCI helps to identify high-risk patients, supports clinical decision-making, and improves prognosis.
- 16 October 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e76003
Open AccessPrognostic Value of the Charlson Comorbidity Index for Mortality and Machine Learning–Based Prediction in Critically Ill Patients with Paralytic Ileus: Retrospective Cohort Study
Background: The burden of paralytic ileus (PI) in the intensive care unit remains high, and the Charlson Comorbidity Index (CCI) is strongly associated with the prognosis of several acute and chronic diseases. However, evidence specifically evaluating the prognostic value of CCI in intensive care unit patients with PI remains limited. Objective: This study aimed to investigate the association between CCI and clinical prognosis in critically ill patients with PI. Methods: In this study, data were extracted from the Medical Information Mart for Intensive Care IV (version 2.2), a large, publicly available critical care database, and used to determine the optimal cut-off value of CCI for predicting mortality in patients with PI using the receiver operating characteristic curves, and the association between CCI and mortality was evaluated using Cox regression and restricted cubic spline analysis. A machine learning (ML) prediction model was then constructed to predict hospital mortality by combining CCI and other clinical characteristics. Results: The study included 863 patients with PI (age: median 65.4, IQR 54.6‐75.5 y; male: 575/863, 66.6%). The receiver operating characteristic curve identified an optimal cut-off value of 4.5 for CCI. The multivariate Cox regression analysis showed that compared to the lowest CCI quartile, patients with elevated CCI levels were more likely to have elevated hospital (Q4: hazard ratio [HR] 2.447, 95% CI 1.210‐4.951), 28-day (Q4: HR 3.891, 95% CI 1.956‐7.740), and 90-day (Q4: HR 3.994, 95% CI 2.224‐7.173) all-cause mortality were significantly associated with elevated CCI levels; however, the association with ICU mortality (Q4: HR 1.892, 95% CI 0.653‐5.480) was weak. Among the 11 ML models, the light gradient boosting machine model performed best, with internal validation results showing an area under the curve of 0.811, a geometric mean of 0.670, and an F 1 -score of 0.895. Conclusions: The CCI is an important predictor of hospital, 28-day, and 90-day all-cause mortality in critically ill patients with PI, and the optimal threshold is 4.5. ML models, including the CCI, show high accuracy in predicting hospital mortality, and the CCI occupies an important position in the model. This suggests that the CCI helps to identify high-risk patients, supports clinical decision-making, and improves prognosis.
- Open Access
- 15 April 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Prognostic value of the Charlson Comorbidity Index for mortality in critically ill patients with paralytic ileus and mortality prediction model using machine learning (Preprint)
BACKGROUND The burden of paralytic ileus (PI) in the intensive care unit (ICU) remains high, and the Charlson Comorbidity Index (CCI) is strongly associated with the prognosis of several acute and chronic diseases. However, there is no literature on the clinical value of CCI as a prognostic assessment tool for critically ill patients with PI in the ICU. OBJECTIVE The aim of this study was to investigate the relationship between CCI and clinical prognosis in critically ill patients with PI. METHODS In this study, data from the Critical Care Medical Information Marketplace IV 2.2 database were used to determine the optimal cutoff value of CCI for predicting mortality in patients with PI using receiver operating characteristic (ROC) curves, and the relationship between CCI and mortality was evaluated using Cox regression and restricted cubic spline analysis. A machine learning (ML) prediction model was then constructed to predict hospital mortality by combining CCI and other clinical characteristics. RESULTS The study included 863 patients with PI (median age 65.4 years [interquartile range 54.6-75.5 years], 66.6% male). The ROC curve identified an optimal cut-off value of 4.5 for CCI. Multivariate Cox regression analysis showed that compared to the lowest CCI quartile, patients with elevated CCI levels were more likely to have elevated hospital (Q4: HR 2.447, 95% CI 1.210-4.951), 28-day (Q4: HR 3. 891, 95% CI 1.956-7.740) and 90-day (Q4: HR 3.994, 95% CI 2.224-7.173) all-cause mortality were significantly associated with elevated CCI levels; however, the association with ICU mortality (Q4: HR 1.892, 95% CI 0.653-5.480) was weak. Among the 11 ML models, the LightGBM model performed best, with internal validation results showing an area under the curve of 0.811, a G-mean of 0.670, and an F1 score of 0.895. CONCLUSIONS The CCI is an important predictor of hospital, 28-day, and 90-day all-cause mortality in critically ill patients with PI, and the optimal threshold is 4.5. ML models including the CCI show high accuracy in predicting hospital mortality, and the CCI occupies an important position in the model. This suggests that the CCI helps to identify high-risk patients, supports clinical decision making, and improves prognosis. CLINICALTRIAL NO
- 15 April 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPrognostic value of the Charlson Comorbidity Index for mortality in critically ill patients with paralytic ileus and mortality prediction model using machine learning (Preprint)
BACKGROUND The burden of paralytic ileus (PI) in the intensive care unit (ICU) remains high, and the Charlson Comorbidity Index (CCI) is strongly associated with the prognosis of several acute and chronic diseases. However, there is no literature on the clinical value of CCI as a prognostic assessment tool for critically ill patients with PI in the ICU. OBJECTIVE The aim of this study was to investigate the relationship between CCI and clinical prognosis in critically ill patients with PI. METHODS In this study, data from the Critical Care Medical Information Marketplace IV 2.2 database were used to determine the optimal cutoff value of CCI for predicting mortality in patients with PI using receiver operating characteristic (ROC) curves, and the relationship between CCI and mortality was evaluated using Cox regression and restricted cubic spline analysis. A machine learning (ML) prediction model was then constructed to predict hospital mortality by combining CCI and other clinical characteristics. RESULTS The study included 863 patients with PI (median age 65.4 years [interquartile range 54.6-75.5 years], 66.6% male). The ROC curve identified an optimal cut-off value of 4.5 for CCI. Multivariate Cox regression analysis showed that compared to the lowest CCI quartile, patients with elevated CCI levels were more likely to have elevated hospital (Q4: HR 2.447, 95% CI 1.210-4.951), 28-day (Q4: HR 3. 891, 95% CI 1.956-7.740) and 90-day (Q4: HR 3.994, 95% CI 2.224-7.173) all-cause mortality were significantly associated with elevated CCI levels; however, the association with ICU mortality (Q4: HR 1.892, 95% CI 0.653-5.480) was weak. Among the 11 ML models, the LightGBM model performed best, with internal validation results showing an area under the curve of 0.811, a G-mean of 0.670, and an F1 score of 0.895. CONCLUSIONS The CCI is an important predictor of hospital, 28-day, and 90-day all-cause mortality in critically ill patients with PI, and the optimal threshold is 4.5. ML models including the CCI show high accuracy in predicting hospital mortality, and the CCI occupies an important position in the model. This suggests that the CCI helps to identify high-risk patients, supports clinical decision making, and improves prognosis. CLINICALTRIAL NO
- 1 January 2025
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 15 (9) , 3854-3870
Metabolic stress-induced dysregulation of the Hippo signaling pathway inhibits the occurrence of hepatocarcinoma
Liver fibrosis is the natural stress response of the liver to injury and a critical intermediate stage in the progression of most liver diseases. Here, we first demonstrated via a retrospective clinical study that the incidence of advanced hepatocellular carcinoma (HCC) was significantly higher in patients infected with hepatitis B virus (HBV) than in those with hepatolenticular degeneration (HLD). Further analyses involving micro RNA (miRNA) and proteomics were conducted to investigate the distinct mechanisms underlying liver fibrosis induced by HBV and HLD. Results showed significant changes in metabolic pathways and molecules, especially in AMP-activated protein kinase (AMPK) and Hippo signaling pathways, which play crucial roles in cellular glucose and lipid metabolism. Characteristic of HLD is a mutation/deletion in the ATPase Copper Transporting Beta (ATP7B) gene. Subsequent studies indicated that the knockdown or overexpression of ATP7B mutants activates the AMPK and Hippo signaling pathways, resulting in the inhibition of proliferation and transformation of HCC cells. AMPK phosphorylation indicates the presence of metabolic stress. Thus, this finding might partly explain why patients with HLD-related liver fibrosis are more likely to develop liver failure rather than HCC, providing new insights into the intricate mechanisms linking metabolic orchestration and tumor development.
- 1 January 2025
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 15 (9) , 3854-3870
Metabolic stress-induced dysregulation of the Hippo signaling pathway inhibits the occurrence of hepatocarcinoma
Liver fibrosis is the natural stress response of the liver to injury and a critical intermediate stage in the progression of most liver diseases. Here, we first demonstrated via a retrospective clinical study that the incidence of advanced hepatocellular carcinoma (HCC) was significantly higher in patients infected with hepatitis B virus (HBV) than in those with hepatolenticular degeneration (HLD). Further analyses involving micro RNA (miRNA) and proteomics were conducted to investigate the distinct mechanisms underlying liver fibrosis induced by HBV and HLD. Results showed significant changes in metabolic pathways and molecules, especially in AMP-activated protein kinase (AMPK) and Hippo signaling pathways, which play crucial roles in cellular glucose and lipid metabolism. Characteristic of HLD is a mutation/deletion in the ATPase Copper Transporting Beta (ATP7B) gene. Subsequent studies indicated that the knockdown or overexpression of ATP7B mutants activates the AMPK and Hippo signaling pathways, resulting in the inhibition of proliferation and transformation of HCC cells. AMPK phosphorylation indicates the presence of metabolic stress. Thus, this finding might partly explain why patients with HLD-related liver fibrosis are more likely to develop liver failure rather than HCC, providing new insights into the intricate mechanisms linking metabolic orchestration and tumor development.